Login to Your Account



Pharma: Clinic Roundup


Thursday, September 6, 2012
• Baxter International Inc., of Deerfield, Ill., said it started dosing patients with malignant solid tumors in a Phase I study of a fully human recombinant anti-macrophage migration inhibitory factor (MIF) monoclonal antibody.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription